<DOC>
	<DOCNO>NCT02661126</DOCNO>
	<brief_summary>The purpose study compare plasma pharmacokinetics ( PK ) single dose MK-3682B [ MK-3682/grazoprevir ( MK-5172 ) /ruzasvir ( MK-8408 ) fix dose combination ( FDC ) ] participant moderate ( Part 1 ) severe ( Part 2 ) renal insufficiency ( RI ) healthy participant .</brief_summary>
	<brief_title>Pharmacokinetics MK-3682B Participants With Moderate Severe Renal Insufficiency ( MK-3682B-030 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>All Participants : Healthy adult male females 1880 year age screen Continuous nonsmoker moderate smoker ( ≤ 20 cigarettes/day equivalent ) agree consume 10 cigarette per day study period Body Mass Index ( BMI ) ≥ 18 ≤ 40.0 kg/m2 Agrees become pregnant father child participation study Females childbearing potential must either abstinent 14 day prior dose throughout study use acceptable birth control method Vasectomized nonvasectomized male must agree use condom spermicide abstain sexual intercourse first dose 90 day dose Males must agree donate sperm dose 90 day dose Moderate Severe RI Participants : Baseline health judge stable base medical history , physical examination , laboratory profile , vital sign , electrocardiogram ( ECGs ) , deem Investigator Has clinically significant change renal status least 1 month prior dose currently previously hemodialysis Moderate RI : baseline eGFR ≥ 30 mL/min/1.73m2 &lt; 60 mL/min/1.73m2 , base Modification Diet Renal Disease ( MDRD ) equation screen Severe RI : baseline eGFR ≥ 15 mL/min/1.73m2 &lt; 30 mL/min/1.73m2 , base MDRD equation screen Healthy Participants : Is within ± 10 year mean age moderate severe RI arm BMI within 10 % mean BMI participant moderate severe RI arm Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign , ECGs , deem Investigator Baseline CLcr ≥ 80 mL/min base CockcroftGault equation screening Is mentally legally incapacitated significant emotional problem time screen History presence clinically significant medical psychiatric condition disease opinion Investigator History illness , opinion Investigator , might confound result study pose additional risk participate study Is female pregnant lactate Positive result urine saliva drug screen urine breath alcohol screen screen checkin unless positive drug screen due prescription drug use approve Investigator Sponsor Positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) Seated heart rate equal low 44 beat per minute ( bpm ) high 100 bpm screening Has renal transplant nephrectomy Donation blood significant blood loss within 56 day prior dose study drug , donation plasma within 7 day prior dose Has participate another clinical trial within 28 day prior dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>